Loading posts...
PSMA therapy with Lutetium-177 in treatment of metastatic prostate cancer
View

PSMA therapy with Lutetium-177 in treatment of metastatic prostate cancer

Prostate cancer is the second most common type of cancer in men. According to the world’s statistics, 1 of 9 men is diagnosed with this disease during the lifetime. It arises as a small localized tumor, but without proper treatment the neoplasm advances and a...
SMOKY RESCUE RELEASES SPRAY TO DEPROGRAM SMOKERS’ BODY FROM THE BRAND THEY SMOKE
View

SMOKY RESCUE RELEASES SPRAY TO DEPROGRAM SMOKERS’ BODY FROM THE BRAND THEY SMOKE

Naples Florida, Smoky Rescue releases an innovative spray to help smokers to get rid of their addiction and help the body to heal the damage from the toxins obtained through cigarettes. The spray deprograms one’s body of tobacco, personalized to the specific c...
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing
View

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

“This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center o...
Evolution of Cancers in France
View

Evolution of Cancers in France

Cancer mortality in France has reduced over the last twenty-five years. Though, cancer is the primary cause of demise in France. In the year 2012, it was estimated that there were around 148,000 deaths caused by cancer: 63,000 women and 85,000 men. Lung cancer...